Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer

Trial Profile

Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Dalotuzumab (Primary) ; MK 0752 (Primary) ; MK 2206 (Primary) ; Ridaforolimus (Primary)
  • Indications Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Nov 2012 Planned end date changed from 1 Apr 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top